Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia
© 2021 The American Geriatrics Society..
BACKGROUND: Older adults are at the highest risk of severe disease and death due to COVID-19. Randomized data have shown that baricitinib improves outcomes in these patients, but focused stratified analyses of geriatric cohorts are lacking. Our objective was to analyze the efficacy of baricitinib in older adults with COVID-19 moderate-to-severe pneumonia.
METHODS: This is a propensity score [PS]-matched retrospective cohort study. Patients from the COVID-AGE and Alba-Score cohorts, hospitalized for moderate-to-severe COVID-19 pneumonia, were categorized in two age brackets of age <70 years old (86 with baricitinib and 86 PS-matched controls) or ≥70 years old (78 on baricitinib and 78 PS-matched controls). Thirty-day mortality rates were analyzed with Kaplan-Meier and Cox proportional hazard models.
RESULTS: Mean age was 79.1 for those ≥70 years and 58.9 for those <70. Exactly 29.6% were female. Treatment with baricitinib resulted in a significant reduction in death from any cause by 48% in patients aged 70 or older, an 18.5% reduction in 30-day absolute mortality risk (n/N: 16/78 [20.5%] baricitinib, 30/78 [38.5%] in PS-matched controls, p < 0.001) and a lower 30-day adjusted fatality rate (HR 0.21; 95% CI 0.09-0.47; p < 0.001). Beneficial effects on mortality were also observed in the age group <70 (8.1% reduction in 30-day absolute mortality risk; HR 0.14; 95% CI 0.03-0.64; p = 0.011).
CONCLUSIONS: Baricitinib is associated with an absolute mortality risk reduction of 18.5% in adults older than 70 years hospitalized with COVID-19 pneumonia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Journal of the American Geriatrics Society - 69(2021), 10 vom: 08. Okt., Seite 2752-2758 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abizanda, Pedro [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.10.2021 Date Revised 06.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jgs.17357 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327817070 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327817070 | ||
| 003 | DE-627 | ||
| 005 | 20231225201624.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jgs.17357 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1092.xml |
| 035 | |a (DE-627)NLM327817070 | ||
| 035 | |a (NLM)34235720 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abizanda, Pedro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2021 | ||
| 500 | |a Date Revised 06.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The American Geriatrics Society. | ||
| 520 | |a BACKGROUND: Older adults are at the highest risk of severe disease and death due to COVID-19. Randomized data have shown that baricitinib improves outcomes in these patients, but focused stratified analyses of geriatric cohorts are lacking. Our objective was to analyze the efficacy of baricitinib in older adults with COVID-19 moderate-to-severe pneumonia | ||
| 520 | |a METHODS: This is a propensity score [PS]-matched retrospective cohort study. Patients from the COVID-AGE and Alba-Score cohorts, hospitalized for moderate-to-severe COVID-19 pneumonia, were categorized in two age brackets of age <70 years old (86 with baricitinib and 86 PS-matched controls) or ≥70 years old (78 on baricitinib and 78 PS-matched controls). Thirty-day mortality rates were analyzed with Kaplan-Meier and Cox proportional hazard models | ||
| 520 | |a RESULTS: Mean age was 79.1 for those ≥70 years and 58.9 for those <70. Exactly 29.6% were female. Treatment with baricitinib resulted in a significant reduction in death from any cause by 48% in patients aged 70 or older, an 18.5% reduction in 30-day absolute mortality risk (n/N: 16/78 [20.5%] baricitinib, 30/78 [38.5%] in PS-matched controls, p < 0.001) and a lower 30-day adjusted fatality rate (HR 0.21; 95% CI 0.09-0.47; p < 0.001). Beneficial effects on mortality were also observed in the age group <70 (8.1% reduction in 30-day absolute mortality risk; HR 0.14; 95% CI 0.03-0.64; p = 0.011) | ||
| 520 | |a CONCLUSIONS: Baricitinib is associated with an absolute mortality risk reduction of 18.5% in adults older than 70 years hospitalized with COVID-19 pneumonia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a baricitinib | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a older adults | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Azetidines |2 NLM | |
| 650 | 7 | |a Janus Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Purines |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a baricitinib |2 NLM | |
| 650 | 7 | |a ISP4442I3Y |2 NLM | |
| 700 | 1 | |a Calbo Mayo, Juan María |e verfasserin |4 aut | |
| 700 | 1 | |a Mas Romero, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Cortés Zamora, Elisa Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Tabernero Sahuquillo, María Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Romero Rizos, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Jurado, Pedro Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Nievas, Ginés |e verfasserin |4 aut | |
| 700 | 1 | |a Campayo Escolano, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Ochoa Serrano, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Flor Alfaro, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a López Bru, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez Ballesteros, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Caldevilla Bernardo, David |e verfasserin |4 aut | |
| 700 | 1 | |a Callejas González, Francisco Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Andrés-Pretel, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Lauschke, Volker Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Stebbing, Justin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Geriatrics Society |d 1953 |g 69(2021), 10 vom: 08. Okt., Seite 2752-2758 |w (DE-627)NLM000041769 |x 1532-5415 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2021 |g number:10 |g day:08 |g month:10 |g pages:2752-2758 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jgs.17357 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2021 |e 10 |b 08 |c 10 |h 2752-2758 | ||